Liver Metastases from Ovarian Cystadenocarcinoma Masquerading on CT as Lobar Fatty Infiltration

Leifer, David M.; Chan, Teresa W.

doi:10.1097/00004728-199309000-00029

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian serous carcinoma is the most common form of epithelial ovarian cancer, and accounts for 40% to 50% of all such tumors, which spread to vital organ parenchyma, such as the lung and liver, and occur in 2-3% of the patients. Furthermore, parenchymal liver metastasis from cystic ovarian adenocarcinoma is very rare (1)(2)(3). The number of studies that have evaluated the benefit of hepatic resection of metachronous metastases from gynecologic cancer is very small, but recently some authors have reported that hepatic resection of metachronous metastases from gynecologic carcinoma can be performed safely, and may help prolong survival in carefully selected patients (4).…”

Section: Introductionmentioning

confidence: 99%

Hepatic Resection of Metastatic Tumor from Serous Cystadenocarcinoma of the Ovary

et al. 2002

View full text Add to dashboard Cite

Metastatic carcinomas are the largest group of malignant tumors of the liver. But parenchymal liver metastasis from cystic ovarian adenocarcinoma is very rare. We report a case in which the resection of metastatic liver neoplasm from ovarian serous cystadenocarcinoma was done 7 yr after initial treatment. A 48-yr-old oriental housewife complained of easy fatigability and right lower quadrant discomfort. The hepatic mass was detected by ultrasonographic examination. Serum albumin, bilirubin, and aspartate aminotransferase/alanine aminotransferase were normal. Alkaline phosphatase level was slightly increased at 146 IU/L. A tumor marker study showed alpha-fetoprotein 0.97 IU/mL, carcinoembryonic antigen 0.965 ng/mL, cancer antigen 125 1,267 ng/mL and CA 19-9 106.1 ng/mL. The operation involved cholecystectomy and segmentectomy VI and VII of the liver. The patient recovered from the surgery without any complication. On the 10th postoperative day, the patient received a single-regimen chemotherapy with paclitaxel (Taxol, 155 mg/m(2) BSA) and was discharged. She has been carefully followed-up without any evidence of recurrence after completion of the remaining 5 cycles of chemo-therapy, at intervals of three weeks.

show abstract

Section: Introductionmentioning

confidence: 99%